Worried about cancer risk with ts/bDMARDs in RA? Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up. Abstract#OP0065 @RheumNow #EULAR2025